13FINSTITUTION · CIK 0001346824 · 2026-Q2 · Filed Aug 14, 2026
Ra Capital Management
RA CAPITAL MANAGEMENT, L.P.
$11.5B
13F long value · 2026-Q2 Positions84
CategoryAsset manager
Quarters tracked9
●#437 of 556 by 13F long value
Size rank 3/10
14NEW5ADD4TRIM16EXIT
Snapshot
Ra Capital Management's 13F portfolio at a glance: size, concentration and this quarter's activity.
13F long value
$11.5B
Positions
84 (1 unmapped)
Top 84 long weight
100.0%
Quarters tracked
9
Latest 13F filed
Aug 14, 2026
New positions
14
Exits / near-exits
16
13F long value by quarter
Reported long equity value each quarter: fund flows plus market moves. Option notional is not included.
Top holdings · 2026-Q2
The fund's largest reported positions.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q2 |
|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S | Ascendis Pharma A/S | 23.8% | $2.7B | 10.3M | +1.9% |
| PBLS Parabilis Medicines, Inc. | Parabilis Medicines, Inc. | 6.9% | $791.9M | 28.9M | +3.9% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | RHYTHM PHARMACEUTICALS, INC. | 6.4% | $740.2M | 6.7M | -3.2% |
| PCVX Vaxcyte, Inc. | Vaxcyte, Inc. | 5.8% | $667.0M | 11.5M | +6.0% |
| SION Sionna Therapeutics, Inc. | Sionna Therapeutics, Inc. | 3.8% | $435.7M | 9.9M | -92.9% |
| TYRA Tyra Biosciences, Inc. | Tyra Biosciences, Inc. | 3.4% | $389.6M | 12.2M | -38.2% |
| EWTX Edgewise Therapeutics, Inc. | Edgewise Therapeutics, Inc. | 3.0% | $341.0M | 8.4M | +7.5% |
| NAMS NewAmsterdam Pharma Co N.V. | NewAmsterdam Pharma Co N.V. | 2.8% | $323.7M | 9.6M | -42.6% |
| COAG Hemab Therapeutics Holdings, Inc. | Hemab Therapeutics Holdings, Inc. | 2.5% | $286.8M | 7.8M | +6.3% |
| SEPN Septerna, Inc. | Septerna, Inc. | 2.0% | $234.3M | 7.0M | +24.4% |
| BCAX Bicara Therapeutics Inc. | Bicara Therapeutics Inc. | 1.9% | $215.4M | 7.3M | -67.2% |
| MLYS Mineralys Therapeutics, Inc. | Mineralys Therapeutics, Inc. | 1.8% | $207.6M | 7.7M | -46.1% |
| GHRS GH Research PLC | GH Research PLC | 1.8% | $205.3M | 7.6M | -30.2% |
| IRON Disc Medicine, Inc. | Disc Medicine, Inc. | 1.6% | $179.2M | 2.5M | +4.7% |
| SGP SpyGlass Pharma, Inc. | SpyGlass Pharma, Inc. | 1.6% | $178.6M | 8.0M | +44.8% |
Quarterly changes · 2026-Q2
What Ra Capital Management opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| NEW | PBLS NEW Parabilis Medicines, Inc. | Parabilis Medicines, Inc. | 0 | 28.9M | New | +$791.9M |
| NEW | COAG NEW Hemab Therapeutics Holdings, Inc. | Hemab Therapeutics Holdings, Inc. | 0 | 7.8M | New | +$286.8M |
| EXIT | DNTH EXIT Dianthus Therapeutics, Inc. /DE/ | Dianthus Therapeutics, Inc. /DE/ | 2.6M | 0 | -100.0% | -$219.2M |
| NEW | ABVX NEW Abivax S.A. | Abivax S.A. | 0 | 1.1M | New | +$150.9M |
| NEW | ORKA NEW Oruka Therapeutics, Inc. | Oruka Therapeutics, Inc. | 0 | 1.6M | New | +$148.0M |
| EXIT | PRAX EXIT Praxis Precision Medicines, Inc. | Praxis Precision Medicines, Inc. | 373.8K | 0 | -100.0% | -$120.4M |
| ADD | ARTV ADD Artiva Biotherapeutics, Inc. | Artiva Biotherapeutics, Inc. | 9.9M | 18.0M | +82.2% | +$110.7M |
| TRIM | NUVL TRIM Nuvalent, Inc. | Nuvalent, Inc. | 2.5M | 1.2M | -50.8% | -$105.7M |
| EXIT | SRPT EXIT Sarepta Therapeutics, Inc. | Sarepta Therapeutics, Inc. | 3.9M | 0 | -100.0% | -$84.9M |
| EXIT | SYRE EXIT Spyre Therapeutics, Inc. | Spyre Therapeutics, Inc. | 1.6M | 0 | -100.0% | -$81.8M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter; rising weight = growing conviction.